Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
Discover what you can learn with our compilation of resources to help expand your education around immuno-oncology. Explore books, clinical practice resources, learning tools, podcasts, videos, and more.
Guide to Cancer Immunotherapy was developed by an expert collection of healthcare professionals and nursing leaders to provide nurses with in-depth knowledge on the principles of immunology, cancer and the immune system, and the history of immunotherapy.
The Oncology Nursing Society’s Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities.
In August 2021, ONS brought together 17 oncology nurses to discuss their experiences with immuno-oncology, precision oncology, and nurse navigation. The goal was to assess their understanding of and identify gaps related to precision oncology and the role of the nurse navigator. This clinical update summarizes the findings of the focus group proceedings.
The drug reference sheets in ONS Voice are a quick guide to newly approved therapies or drugs with new indications. This resource from ONS clinical staff provides information through a nursing lens and includes the drug’s indication, side-effect profile, nursing considerations, patient education talking points, and more.
Tune in and tune up your practice with the Oncology Nursing Podcast. ONS’s popular podcast features weekly episodes with subject matter experts from all facets of oncology care.
This fourth edition of Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook provides a detailed overview of the mechanisms, side effects, and administration of myriad treatments to assist clinicians in providing comprehensive care to patients with cancer.
Patients with uveal melanoma who were treated with tebentafusp, an investigational immunotherapy, lived a median 5.7 months longer than those in comparison groups, researchers reported in study findings presented at the American Association for Cancer Research 2021 annual meeting.